Xaira Therapeutics
CA - South SFBiotechnology
Focus: Xaira Therapeutics is an AI-driven drug discovery company founded in 2024, leveraging virtual cell models and genome-wide perturbation datasets to accelerate therapeutic development. The company focuses on ophthalmology, neurology, and gene therapy with a recent ~$1B fundraise positioning it as a well-capitalized pre-clinical stage innovator.
Profile data last refreshed 8h ago · AI intelligence enriched 3w ago
Open Jobs
19
Should You Work at Xaira Therapeutics?
AI assessmentXaira is a high-risk, high-reward early-stage bet suited for scientists and engineers seeking equity upside and AI/drug-discovery innovation exposure, but not for those prioritizing near-term revenue growth or organizational stability.
Why Work Here
- Ground-floor opportunity at a newly-founded (2024) AI-first biotech with ~$1B in capital, enabling you to shape company culture and scientific direction from inception.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Xaira Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.